Sylvester Stallone TRT: How a Regular Patient Would Get the Same Access

What Stallone Has Actually Said About TRT

Stallone is one of the most recognizable public figures to speak about testosterone therapy without apology. His comments are worth examining as a clinical starting point, not celebrity gossip.

The 2008 Australia Incident

In February 2007, Australian customs officers found 48 vials of Jintropin (a brand of human growth hormone) and testosterone in Stallone's luggage at Sydney Airport. He was fined AUD $10,600. In interviews following the incident, Stallone told Time Magazine: "HGH is nothing. Everyone over 40 years old would be wise to investigate it because it helps in so many ways." He framed testosterone similarly, as a quality-of-life tool rather than a performance drug.

This matters clinically because Stallone was approximately 60 at the time. Testosterone decline in men accelerates after age 40, with total testosterone falling roughly 1 to 2% per year according to data from the Baltimore Longitudinal Study of Aging published by the National Institute on Aging (NIH longitudinal aging data).

Later Public Statements

In a 2015 interview with Muscle and Fitness, Stallone described testosterone as part of his recovery and longevity approach after age 50. He has not published specific dose or protocol details in verified public statements. Any claim about his exact regimen beyond what he has personally confirmed should be treated as inference.

The framework below separates what Stallone confirmed, what is clinically reasonable to infer, and what any patient would need to do independently to access equivalent care.

| Claim | Source | Clinical Status | |---|---|---| | Uses testosterone therapy | Stallone public interviews | Confirmed | | Uses HGH | 2007 Australian customs record | Confirmed (legal in U.S. Under prescription) | | Specific dose or protocol | No verified source | Unconfirmed; do not replicate without evaluation | | Celebrity-exclusive access | N/A | False. Standard TRT is available to any qualifying patient |

Why Men Over 40 Develop Low Testosterone

Testosterone does not drop suddenly. The decline is gradual and often goes undiagnosed for years because symptoms overlap with normal aging.

The Physiology of Decline

The hypothalamic-pituitary-gonadal axis regulates testosterone production. As men age, Leydig cell function in the testes decreases, and the pulsatile release of luteinizing hormone (LH) from the pituitary becomes less efficient. The result is lower total and free testosterone alongside symptoms that can include fatigue, reduced libido, decreased muscle mass, increased body fat, and mood changes. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism defines male hypogonadism as a clinical syndrome resulting from failure to produce physiological levels of testosterone.

Prevalence Data

The Massachusetts Male Aging Study found that 39% of men aged 45 and older met at least one biochemical criterion for hypogonadism (PMID 17062768). A 2006 analysis published in the International Journal of Clinical Practice estimated that symptomatic androgen deficiency affects 2 to 6 million men in the United States, with the majority undiagnosed (PMID 16805773).

Symptoms That Warrant Lab Testing

A patient does not need to look like Sylvester Stallone to qualify for evaluation. The American Urological Association (AUA) 2018 guideline states that testing is appropriate for men presenting with any of the following: low energy, decreased libido, erectile dysfunction, depressed mood, decreased muscle mass, or increased body fat with no other clear cause (AUA Testosterone Deficiency Guideline).

The Diagnostic Process: Labs and Thresholds

Getting the same standard of care Stallone describes starts with blood work. No physician can legally or ethically prescribe testosterone without documented biochemical deficiency in the United States.

Which Labs Are Required

The standard initial panel includes:

• Total testosterone (drawn before 10 a.m., when levels peak)
• Free testosterone (calculated or by equilibrium dialysis)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Complete blood count (baseline hematocrit before therapy)
• Prostate-specific antigen (PSA) for men over 40
• Comprehensive metabolic panel
• Sex hormone-binding globulin (SHBG) (affects free testosterone calculation)

The Endocrine Society guideline recommends confirming low testosterone on two separate morning measurements before initiating therapy (PMID 30272583).

What "Low" Actually Means

The AUA defines low testosterone as a total level below 300 ng/dL. The Endocrine Society uses a slightly different threshold based on the specific assay used by each laboratory. Free testosterone below 65 pg/mL may indicate deficiency even when total testosterone appears borderline normal, particularly in men with elevated SHBG (PMID 30272583).

A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that free testosterone measurement by equilibrium dialysis identified hypogonadism in 15.4% of men whose total testosterone appeared normal (PMID 30272583).

Red Flags That Require Specialist Referral

Men with PSA above 4 ng/mL, a palpable prostate nodule, or a history of prostate cancer should see a urologist before any testosterone is prescribed. Active breast cancer also contraindicates TRT absolutely. The FDA-approved labeling for testosterone products lists these contraindications explicitly (FDA testosterone label).

Approved Testosterone Formulations and Typical Doses

Once diagnosed, a patient has several FDA-approved delivery options. Each has a different pharmacokinetic profile, and the choice depends on patient preference, lifestyle, and physician judgment.

Injectable Testosterone

Testosterone cypionate (Depo-Testosterone) and testosterone enanthate are the two most common injectable forms. Both are FDA-approved, generic, and inexpensive.

• Testosterone cypionate: typically 100 to 200 mg intramuscularly every 1 to 2 weeks, or 50 to 100 mg weekly for more stable blood levels
• Testosterone enanthate: similar dosing range, half-life approximately 4 to 5 days vs. 8 days for cypionate

Weekly injections produce fewer peaks and troughs than biweekly dosing. A 2020 review in Translational Andrology and Urology confirmed that weekly cypionate produces more consistent trough levels (PMID 32420092).

Topical Gels and Creams

AndroGel 1% and 1.62% (testosterone gel) are FDA-approved for once-daily application. The 1.62% formulation delivers 20.25 to 81 mg of testosterone per day depending on the number of pump actuations. Transference to female partners or children is a documented risk; patients must cover application sites after use (FDA AndroGel label).

Pellet Implants

Testosterone pellets (Testopel) are inserted subcutaneously in the buttock under local anesthesia, typically every 3 to 6 months. Each pellet delivers approximately 3 to 4 mg of testosterone per day. The procedure is office-based and takes under 15 minutes. A 2012 study in Therapeutic Advances in Urology found sustained testosterone levels in the normal range for an average of 4.7 months per insertion cycle (PMID 22956993).

Nasal Gel

Natesto is an FDA-approved 4.5% testosterone nasal gel dosed three times daily. It preserves intratesticular testosterone production better than other formulations, which may matter for men concerned about fertility (PMID 27081160).

Monitoring Protocol Once Therapy Starts

TRT is not a set-and-forget prescription. Every major guideline requires ongoing laboratory monitoring.

Early Monitoring (First 3 Months)

The AUA guideline recommends checking testosterone levels 3 to 6 weeks after initiating injectable therapy, or 2 to 4 weeks after starting topical formulations. The target range is 400 to 700 ng/dL for total testosterone, with most guidelines accepting up to 900 ng/dL as physiological. Hematocrit must also be checked at 3 to 6 weeks: if it rises above 54%, therapy should be paused or the dose reduced to avoid increased thrombosis risk (AUA 2018 guideline).

Long-Term Monitoring (Every 6 to 12 Months)

Stable patients require the following at least annually:

• Total and free testosterone
• Complete blood count (hematocrit surveillance)
• PSA
• Digital rectal exam if PSA is trending upward
• Lipid panel (testosterone may reduce HDL in some patients)
• Bone mineral density at baseline and every 1 to 2 years in men with osteoporosis risk

The Endocrine Society guideline states: "We recommend measuring hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, stop therapy until hematocrit decreases to a safe level." (PMID 30272583)

Managing Estradiol

Testosterone aromatizes to estradiol. Men on TRT can develop elevated estradiol, causing gynecomastia, water retention, or mood changes. Monitoring estradiol (sensitive assay, not standard immunoassay) every 6 months allows dose adjustment or the selective addition of an aromatase inhibitor such as anastrozole 0.5 mg twice weekly if clinically indicated. The Endocrine Society does not routinely recommend prophylactic aromatase inhibitors; they should be reserved for symptomatic cases (PMID 30272583).

Cardiovascular Considerations: What the Evidence Actually Shows

This is the area where popular press coverage has been most inconsistent, so precision matters.

The TRAVERSE Trial

The TRAVERSE trial (N=5,246, mean age 65.6 years) was the largest randomized controlled trial of testosterone therapy in men with hypogonadism and pre-existing or high cardiovascular risk. Published in the New England Journal of Medicine in 2023, it found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) at a median follow-up of 33 months (PMID 37256976). The FDA subsequently updated testosterone product labeling to reflect this data.

The trial did find a higher rate of atrial fibrillation (3.5% vs. 2.4%, P<0.001) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone group, which requires discussion during informed consent. Men with a history of atrial fibrillation or deep vein thrombosis need individualized risk assessment before starting TRT.

Erythrocytosis Risk

Hematocrit elevation above 54% occurred in 6.6% of testosterone-treated men in TRAVERSE vs. 1.5% in the placebo group (PMID 37256976). This is the most common laboratory abnormality on TRT and the primary reason hematocrit monitoring is non-negotiable.

How Telehealth TRT Access Works in 2025

The pathway Stallone used almost certainly involved private concierge or sports medicine physicians. That model still exists, but telehealth has made equivalent clinical evaluation accessible without a celebrity budget.

The Standard Telehealth Pathway

1. Online intake form: medical history, symptom questionnaire, current medications
2. Lab order: the physician orders a testosterone panel at a local Quest or LabCorp site, typically without requiring an in-person visit first
3. Physician review: a board-certified physician reviews labs and conducts a synchronous or asynchronous consultation
4. Prescription: if labs confirm hypogonadism and there are no contraindications, testosterone is prescribed and shipped to a pharmacy or directly to the patient
5. Follow-up labs: required at 3 to 6 weeks, then every 6 months

Most U.S. States permit telehealth prescribing of testosterone as a Schedule III controlled substance. A small number of states require an in-person exam for controlled substance prescriptions; patients should verify their state's rules.

Cost Comparison

Generic testosterone cypionate 200 mg/mL (10 mL vial) costs $30, $60 at most retail pharmacies with a GoodRx discount. Monthly injection supply at 100 mg/week runs approximately $12, $25. Lab monitoring adds $50, $150 per panel depending on insurance. Annual all-in costs for generic injectable TRT with monitoring typically run $500, $1,500 per year, compared with $3,000, $8,000 per year for branded gel formulations without insurance.

What a Concierge Physician Adds

Men who prefer in-person care from a sports medicine or anti-aging physician can access more frequent monitoring, compounded testosterone formulations (which are not FDA-approved but may offer different delivery options), and adjunctive therapies such as human chorionic gonadotropin (hCG) to preserve testicular volume and fertility. HCG is available by prescription as Pregnyl or Novarel, or as a compounded formulation. It stimulates intratesticular testosterone production by mimicking LH.

Fertility Preservation: The One Thing Stallone Likely Did Not Need to Worry About

Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and leading to azoospermia or severe oligospermia in most men within 3 to 6 months. For men who have completed family planning, this is not a concern. For men who want future fertility, co-administration of hCG 500 to 1,000 IU three times weekly can maintain sperm production during TRT. A 2013 study in the Journal of Urology found that hCG co-treatment maintained spermatogenesis in 100% of hypogonadal men on testosterone therapy over 26 weeks (PMID 23177502).

Men considering TRT who have not completed family planning should discuss sperm banking before initiating therapy.

Practical Steps to Start the Process Today

Getting evaluated for TRT does not require a personal physician who works with film studios.

The shortest path to diagnosis:

1. Request a morning testosterone panel from a primary care physician or order through a telehealth service
2. Ensure the draw happens before 10 a.m.
3. If total testosterone is below 300 ng/dL, request a repeat measurement on a separate morning
4. Ask for LH, FSH, SHBG, CBC, PSA, and a metabolic panel at the same time
5. Bring symptom data: standardized tools such as the ADAM questionnaire (Androgen Deficiency in Aging Males) or the AMS (Aging Males' Symptoms) scale give physicians objective documentation of symptom burden

The Endocrine Society's 2018 guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." (PMID 30272583)

Confirmed hypogonadism with documented symptoms clears the diagnostic bar. From that point, the prescription pathway is identical whether the patient is a construction worker or a film actor.